Symbols / CTSO
CTSO Chart
About
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 43.33M |
| Enterprise Value | 62.21M | Income | -10.27M | Sales | 36.98M |
| Book/sh | 0.14 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 149 | IPO | — |
| P/E | — | Forward P/E | -4.93 | PEG | — |
| P/S | 1.17 | P/B | 4.79 | P/C | — |
| EV/EBITDA | -4.90 | EV/Sales | 1.68 | Quick Ratio | 1.48 |
| Current Ratio | 2.11 | Debt/Eq | 300.84 | LT Debt/Eq | — |
| EPS (ttm) | -0.18 | EPS next Y | -0.14 | EPS Growth | — |
| Revenue Growth | 10.10% | Earnings | 2026-03-30 | ROA | -19.01% |
| ROE | -93.26% | ROIC | — | Gross Margin | 70.80% |
| Oper. Margin | -28.07% | Profit Margin | -27.77% | Shs Outstand | 62.80M |
| Shs Float | 54.92M | Short Float | 3.52% | Short Ratio | 23.21 |
| Short Interest | — | 52W High | 1.39 | 52W Low | 0.60 |
| Beta | 1.41 | Avg Volume | 99.87K | Volume | 61.44K |
| Target Price | $5.25 | Recom | None | Prev Close | $0.68 |
| Price | $0.69 | Change | 1.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.25
Mean price target
2. Current target
$0.69
Latest analyst target
3. DCF / Fair value
$-1.93
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.69
Low
$0.75
High
$10.00
Mean
$5.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-12-16 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-11-14 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-16 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-20 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-08 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-07-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-05-02 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-03 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-02-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-13 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-03 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2024-11-08 | main | EF Hutton | Buy → Buy | $10 |
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire hu, 13 Nov 2025 08
- CytoSorbents (NASDAQ: CTSO) to present at Jefferies Healthcare Conference in London - Stock Titan Mon, 17 Nov 2025 08
- CytoSorbents reports Q4 and full-year 2025 revenue expectations - Investing.com Mon, 12 Jan 2026 08
- CytoSorbents Corp (CTSO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance hu, 13 Nov 2025 08
- Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower - simplywall.st hu, 13 Nov 2025 08
- Cytosorbents (CTSO) Q3 2025 Earnings Transcript - The Globe and Mail hu, 13 Nov 2025 08
- CytoSorbents to Participate at the Jefferies Global Healthcare C - GuruFocus hu, 29 May 2025 07
- How interest rate cuts could boost CTSO stock - 2025 Price Targets & Smart Investment Allocation Tips - mfd.ru Wed, 11 Feb 2026 19
- The past five years for Cytosorbents (NASDAQ:CTSO) investors has not been profitable - Yahoo Finance Sat, 20 Sep 2025 07
- CTSO: CytoSorbents reports 4th quarter and 2024 financial results which showed impressive product revenue growth that was above our expectations. - Research Tree Fri, 04 Apr 2025 07
- CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances - The Globe and Mail Fri, 14 Nov 2025 08
- Cytosorbents Corp Q2 2025 Earnings Call Highlights - The Globe and Mail Wed, 13 Aug 2025 07
- Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga Wed, 20 Aug 2025 07
- Cytosorbents receives Nasdaq notice for non-compliance with minimum bid price - Investing.com Fri, 03 Oct 2025 07
- Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance Sat, 14 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 100000 | 64000 | — | Stock Award(Grant) at price 0.64 per share. | CHAN PHILLIP P | Chief Executive Officer | — | 2025-11-18 00:00:00 | D |
| 1 | 105600 | — | — | Stock Award(Grant) at price 0.00 per share. | CHAN PHILLIP P | Chief Executive Officer | — | 2025-08-08 00:00:00 | D |
| 2 | 70000 | — | — | Stock Award(Grant) at price 0.00 per share. | DELIARGYRIS EFTHYMIOS | Officer | — | 2025-08-08 00:00:00 | D |
| 3 | 89100 | — | — | Stock Award(Grant) at price 0.00 per share. | CAPPONI VINCENT J | President | — | 2025-08-08 00:00:00 | D |
| 4 | 71500 | — | — | Stock Award(Grant) at price 0.00 per share. | MARIANI PETER J | Chief Financial Officer | — | 2025-08-08 00:00:00 | D |
| 5 | 34168 | 38610 | — | Conversion of Exercise of derivative security at price 1.13 per share. | CHAN PHILLIP P | Chief Executive Officer | — | 2025-02-24 00:00:00 | D |
| 6 | 21950 | 24804 | — | Conversion of Exercise of derivative security at price 1.13 per share. | SOBEL ALAN D | Director | — | 2025-02-24 00:00:00 | D |
| 7 | 10000 | 11300 | — | Conversion of Exercise of derivative security at price 1.13 per share. | BATOR MICHAEL G. | Director | — | 2025-02-24 00:00:00 | D |
| 8 | 12000 | 13560 | — | Conversion of Exercise of derivative security at price 1.13 per share. | CAPPONI VINCENT J | President | — | 2025-02-24 00:00:00 | D |
| 9 | 32625 | 36866 | — | Conversion of Exercise of derivative security at price 1.13 per share. | MARIANI PETER J | Chief Financial Officer | — | 2025-02-24 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -321.08K | 52.63K | -78.35K | -72.18K |
| TaxRateForCalcs | 0.08 | 0.03 | 0.03 | 0.03 |
| NormalizedEBITDA | -15.04M | -29.83M | -27.94M | -19.04M |
| TotalUnusualItems | -4.22M | 1.95M | -2.45M | -2.58M |
| TotalUnusualItemsExcludingGoodwill | -4.22M | 1.95M | -2.45M | -2.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.72M | -29.25M | -32.81M | -24.56M |
| ReconciledDepreciation | 1.74M | 2.02M | 1.13M | 1.13M |
| ReconciledCostOfRevenue | 10.47M | 9.13M | 13.96M | 11.05M |
| EBITDA | -19.27M | -27.88M | -30.39M | -21.62M |
| EBIT | -21.01M | -29.90M | -31.52M | -22.74M |
| NetInterestIncome | -1.40M | -157.89K | 132.60K | 28.01K |
| InterestExpense | 1.40M | 157.89K | ||
| InterestIncome | 28.01K | |||
| NormalizedIncome | -16.82M | -31.14M | -30.44M | -22.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.72M | -29.25M | -32.81M | -24.56M |
| TotalExpenses | 52.38M | 63.03M | 60.88M | 62.85M |
| TotalOperatingIncomeAsReported | -16.79M | -31.95M | -31.52M | -22.74M |
| DilutedAverageShares | 54.43M | 44.66M | 43.79M | 43.57M |
| BasicAverageShares | 54.43M | 44.66M | 43.79M | 43.57M |
| DilutedEPS | -0.38 | -0.65 | -0.75 | -0.57 |
| BasicEPS | -0.38 | -0.65 | -0.75 | -0.57 |
| DilutedNIAvailtoComStockholders | -20.72M | -29.25M | -32.81M | -24.56M |
| NetIncomeCommonStockholders | -20.72M | -29.25M | -32.81M | -24.56M |
| NetIncome | -20.72M | -29.25M | -32.81M | -24.56M |
| NetIncomeIncludingNoncontrollingInterests | -20.72M | -29.25M | -32.81M | -24.56M |
| NetIncomeContinuousOperations | -20.72M | -29.25M | -32.81M | -24.56M |
| TaxProvision | -1.69M | -813.74K | -1.09M | -736.00K |
| PretaxIncome | -22.41M | -30.06M | -33.91M | -25.29M |
| OtherIncomeExpense | -4.22M | 2.05M | -2.52M | -2.58M |
| OtherNonOperatingIncomeExpenses | -30.00 | 96.75K | -67.30K | |
| GainOnSaleOfSecurity | -4.22M | 1.95M | -2.45M | -2.58M |
| NetNonOperatingInterestIncomeExpense | -1.40M | -157.89K | 132.60K | 28.01K |
| TotalOtherFinanceCost | 157.89K | -132.60K | -28.01K | |
| InterestExpenseNonOperating | 1.40M | 157.89K | ||
| InterestIncomeNonOperating | 28.01K | |||
| OperatingIncome | -16.79M | -31.95M | -31.52M | -22.74M |
| OperatingExpense | 41.91M | 53.90M | 46.93M | 51.81M |
| OtherOperatingExpenses | -5.26M | -5.33M | -3.06M | |
| ResearchAndDevelopment | 6.92M | 15.59M | 15.12M | 16.38M |
| SellingGeneralAndAdministration | 35.00M | 38.31M | 37.14M | 38.48M |
| GeneralAndAdministrativeExpense | 37.87M | 37.14M | 38.48M | |
| OtherGandA | 37.87M | 37.14M | 38.48M | |
| GrossProfit | 25.13M | 21.95M | 15.40M | 29.06M |
| CostOfRevenue | 10.47M | 9.13M | 13.96M | 11.05M |
| TotalRevenue | 35.59M | 31.08M | 29.36M | 40.11M |
| OperatingRevenue | 35.59M | 31.08M | 29.36M | 40.11M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 55.10M | 54.51M | 43.85M | 43.69M |
| ShareIssued | 55.10M | 54.51M | 43.85M | 43.69M |
| NetDebt | 10.72M | |||
| TotalDebt | 26.89M | 18.31M | 18.25M | 13.82M |
| TangibleBookValue | 7.36M | 19.57M | 30.98M | 57.88M |
| InvestedCapital | 25.10M | 28.52M | 40.37M | 62.58M |
| WorkingCapital | 11.78M | 11.36M | 24.05M | 50.61M |
| NetTangibleAssets | 7.36M | 19.57M | 30.98M | 57.88M |
| CapitalLeaseObligations | 12.90M | 13.27M | 13.25M | 13.82M |
| CommonStockEquity | 11.11M | 23.48M | 35.37M | 62.58M |
| TotalCapitalization | 25.10M | 26.02M | 40.37M | 62.58M |
| TotalEquityGrossMinorityInterest | 11.11M | 23.48M | 35.37M | 62.58M |
| StockholdersEquity | 11.11M | 23.48M | 35.37M | 62.58M |
| GainsLossesNotAffectingRetainedEarnings | 4.25M | 529.32K | 2.33M | 525.59K |
| OtherEquityAdjustments | 4.25M | 529.32K | 2.33M | 525.59K |
| RetainedEarnings | -304.01M | -283.29M | -254.00M | -221.19M |
| AdditionalPaidInCapital | 310.81M | 306.19M | 287.00M | 283.19M |
| CapitalStock | 54.83K | 54.24K | 43.63K | 43.48K |
| CommonStock | 54.83K | 54.24K | 43.63K | 43.48K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 36.26M | 29.48M | 27.86M | 26.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.44M | 15.44M | 18.14M | 13.25M |
| LongTermDebtAndCapitalLeaseObligation | 26.44M | 15.44M | 18.14M | 13.25M |
| LongTermCapitalLeaseObligation | 12.44M | 12.90M | 13.14M | 13.25M |
| LongTermDebt | 14.00M | 2.54M | 5.00M | |
| CurrentLiabilities | 9.82M | 14.04M | 9.71M | 13.69M |
| OtherCurrentLiabilities | 865.51K | 991.54K | ||
| CurrentDeferredLiabilities | 419.33K | 1.38M | 1.52M | 2.16M |
| CurrentDeferredRevenue | 419.33K | 1.38M | 1.52M | 2.16M |
| CurrentDebtAndCapitalLeaseObligation | 452.69K | 2.87M | 108.94K | 570.57K |
| CurrentCapitalLeaseObligation | 452.69K | 373.64K | 108.94K | 570.57K |
| CurrentDebt | 2.50M | |||
| OtherCurrentBorrowings | 2.50M | |||
| PayablesAndAccruedExpenses | 8.09M | 8.79M | 8.09M | 10.96M |
| CurrentAccruedExpenses | 4.75M | 4.99M | 5.58M | 7.11M |
| InterestPayable | 34.44K | 5.56K | 0.00 | |
| Payables | 3.34M | 3.80M | 2.51M | 3.85M |
| OtherPayable | 21.87K | 785.82K | ||
| AccountsPayable | 3.34M | 3.80M | 2.51M | 3.85M |
| TotalAssets | 47.37M | 52.96M | 63.23M | 89.52M |
| TotalNonCurrentAssets | 25.77M | 27.56M | 29.47M | 25.22M |
| OtherNonCurrentAssets | 1.48M | 1.48M | 1.69M | 1.69M |
| NonCurrentPrepaidAssets | 22.64K | 52.05K | 46.91K | 256.59K |
| GoodwillAndOtherIntangibleAssets | 3.75M | 3.91M | 4.39M | 4.70M |
| OtherIntangibleAssets | 3.75M | 3.91M | 4.39M | 4.70M |
| NetPPE | 20.51M | 22.12M | 23.35M | 18.57M |
| AccumulatedDepreciation | -4.22M | -3.04M | -1.90M | -4.76M |
| GrossPPE | 24.74M | 25.15M | 25.24M | 23.33M |
| Leases | 6.28M | 6.22M | 6.20M | 2.62M |
| OtherProperties | 11.51M | 12.06M | 12.60M | 13.42M |
| MachineryFurnitureEquipment | 6.94M | 6.87M | 6.44M | 7.29M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 21.60M | 25.40M | 33.76M | 64.30M |
| OtherCurrentAssets | 3.27M | 1.83M | 2.49M | 2.87M |
| RestrictedCash | 5.00M | 0.00 | ||
| PrepaidAssets | 2.87M | |||
| Inventory | 2.73M | 3.38M | 3.46M | 4.77M |
| OtherInventories | -304.31K | |||
| FinishedGoods | 1.96M | 1.85M | 1.57M | |
| WorkInProcess | 502.52K | 838.87K | 1.28M | |
| RawMaterials | 569.82K | 685.80K | 613.35K | |
| Receivables | 7.32M | 6.06M | 5.66M | 4.52M |
| AccountsReceivable | 7.32M | 6.06M | 5.66M | 4.52M |
| AllowanceForDoubtfulAccountsReceivable | -157.70K | -49.66K | -76.04K | -60.54K |
| GrossAccountsReceivable | 7.48M | 6.11M | 5.74M | 4.58M |
| CashCashEquivalentsAndShortTermInvestments | 3.28M | 14.13M | 22.14M | 52.14M |
| CashAndCashEquivalents | 3.28M | 14.13M | 22.14M | 52.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.10M | -22.59M | -34.69M | -18.29M |
| RepurchaseOfCapitalStock | -40.36K | -90.00K | ||
| RepaymentOfDebt | -5.00M | 0.00 | 0.00 | 0.00 |
| IssuanceOfDebt | 15.00M | 0.00 | 5.00M | 0.00 |
| IssuanceOfCapitalStock | 178.65K | 14.26M | ||
| CapitalExpenditure | -669.43K | -936.24K | -6.46M | -4.28M |
| InterestPaidSupplementalData | 1.29M | 376.67K | 0.00 | 0.00 |
| EndCashPosition | 9.76M | 15.62M | 23.83M | 53.83M |
| BeginningCashPosition | 15.62M | 23.83M | 53.83M | 71.42M |
| EffectOfExchangeRateChanges | -84.68K | -99.77K | -262.92K | -24.77K |
| ChangesInCash | -5.77M | -8.12M | -29.73M | -17.57M |
| FinancingCashFlow | 9.33M | 14.47M | 4.96M | 715.20K |
| CashFlowFromContinuingFinancingActivities | 9.33M | 14.47M | 4.96M | 715.20K |
| NetOtherFinancingCharges | -847.95K | |||
| ProceedsFromStockOptionExercised | 0.00 | 218.28K | 0.00 | 805.20K |
| NetCommonStockIssuance | 178.65K | 14.26M | -40.36K | -90.00K |
| CommonStockPayments | -40.36K | -90.00K | ||
| CommonStockIssuance | 178.65K | 14.26M | ||
| NetIssuancePaymentsOfDebt | 10.00M | 0.00 | 5.00M | 0.00 |
| NetLongTermDebtIssuance | 10.00M | 0.00 | 5.00M | 0.00 |
| LongTermDebtPayments | -5.00M | 0.00 | 0.00 | 0.00 |
| LongTermDebtIssuance | 15.00M | 0.00 | 5.00M | 0.00 |
| InvestingCashFlow | -669.43K | -936.24K | -6.46M | -4.28M |
| CashFlowFromContinuingInvestingActivities | -669.43K | -936.24K | -6.46M | -4.28M |
| NetIntangiblesPurchaseAndSale | -385.09K | -398.12K | -368.21K | -640.01K |
| PurchaseOfIntangibles | -385.09K | -398.12K | -368.21K | -640.01K |
| NetPPEPurchaseAndSale | -284.34K | -538.12K | -6.09M | -3.64M |
| PurchaseOfPPE | -284.34K | -538.12K | -6.09M | -3.64M |
| OperatingCashFlow | -14.43M | -21.66M | -28.23M | -14.01M |
| CashFlowFromContinuingOperatingActivities | -14.43M | -21.66M | -28.23M | -14.01M |
| ChangeInWorkingCapital | -4.38M | 2.65M | -3.56M | 641.90K |
| ChangeInOtherCurrentAssets | 1.05K | -49.00 | 52.68K | -135.86K |
| ChangeInPayablesAndAccruedExpense | -1.81M | 1.61M | -3.25M | 2.43M |
| ChangeInPrepaidAssets | -1.35M | 1.10M | -22.19K | 280.92K |
| ChangeInInventory | 500.47K | 183.27K | 945.35K | -2.35M |
| ChangeInReceivables | -1.72M | -245.62K | -1.29M | 420.58K |
| ChangesInAccountReceivables | -1.29M | 420.58K | ||
| OtherNonCashItems | 492.15K | 42.86K | ||
| StockBasedCompensation | 3.76M | 4.16M | 3.80M | 6.20M |
| AssetImpairmentCharge | 448.90K | 670.12K | 627.25K | -512.00 |
| DepreciationAmortizationDepletion | 1.74M | 2.02M | 1.13M | 1.13M |
| DepreciationAndAmortization | 1.74M | 2.02M | 1.13M | 1.13M |
| Depreciation | 1.74M | 2.02M | 1.13M | 1.13M |
| OperatingGainsLosses | 4.22M | -1.95M | 2.58M | 2.58M |
| NetForeignCurrencyExchangeGainLoss | 4.22M | -1.95M | 2.45M | 2.58M |
| GainLossOnSaleOfPPE | 0.00 | 132.30K | 0.00 | |
| NetIncomeFromContinuingOperations | -20.72M | -29.25M | -32.81M | -24.56M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CTSO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|